Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara Research consensus. Sanofi reported a business operating profit of 2.58 billion euros in the year-earlier period.
Sanofi plans 5 billion euro buyback, sees higher profit growth
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs such as its respiratory syncytial virus (RSV) shot.
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale and plans €5B share buyback.
French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans for a 5 billion euro ($5.5 billion) share buyback program in 2025. The ...
The Board of Directors met on January 29, 2025; proposes a dividend of EUR 3.92 for 2024, 30th year of consecutive increasesInvest with ...
We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for ...
Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback